A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.
A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.
复制标题
DOI：
10.1080/21645515.2022.2127292
复制
发表时间：
2022-11-30
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
2019冠状病毒病（COVID-19）大流行表明，迫切需要有效的预防性疫苗接种，以防止严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）的传播。鼻内疫苗接种是预防COVID-19的一种有吸引力的方法，因为鼻粘膜是SARS-CoV-2最初进入和病毒复制的部位，然后吸入肺部。我们先前证明，单一鼻内施用编码SARS-CoV-2刺突蛋白受体结合结构域的候选5型腺病毒载体疫苗（AdCOVID）在气道粘膜和外周中诱导稳健的免疫，并且完全保护K18-hACE 2小鼠免受致死SARS-CoV-2攻击。在这里，我们表明，单次鼻内施用AdCOVID限制了K18-hACE 2小鼠鼻腔中的病毒复制。AdCOVID还诱导小鼠肺中的杀菌免疫，这反映在没有感染性病毒。最后，AdCOVID预防SARS-CoV-2诱导的小鼠肺部病理损伤。这些数据表明，AdCOVID不仅限制了呼吸道中的病毒复制，而且还预防了SARS-CoV-2感染后病毒诱导的炎症和免疫病理学。
The coronavirus disease 2019 (COVID-19) pandemic has illustrated the critical need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive approach for preventing COVID-19 as the nasal mucosa is the site of initial SARS-CoV-2 entry and viral replication prior to aspiration into the lungs. We previously demonstrated that a single intranasal administration of a candidate adenovirus type 5-vectored vaccine encoding the receptor-binding domain of the SARS-CoV-2 spike protein (AdCOVID) induced robust immunity in both the airway mucosa and periphery, and completely protected K18-hACE2 mice from lethal SARS-CoV-2 challenge. Here we show that a single intranasal administration of AdCOVID limits viral replication in the nasal cavity of K18-hACE2 mice. AdCOVID also induces sterilizing immunity in the lungs of mice as reflected by the absence of infectious virus. Finally, AdCOVID prevents SARS-CoV-2 induced pathological damage in the lungs of mice. These data show that AdCOVID not only limits viral replication in the respiratory tract, but it also prevents virus-induced inflammation and immunopathology following SARS-CoV-2 infection.
登录
查看更多内容
影响因子：
64.5
作者：
Hou, Yixuan J.;Okuda, Kenichi;Baric, Ralph S.
通讯作者：
Baric, Ralph S.
影响因子：
3.7
作者：
Kawasuji H;Takegoshi Y;Kaneda M;Ueno A;Miyajima Y;Kawago K;Fukui Y;Yoshida Y;Kimura M;Yamada H;Sakamaki I;Tani H;Morinaga Y;Yamamoto Y
通讯作者：
Yamamoto Y
对新型冠状病毒（SARS-COV-2）疫苗的粘膜和血清学免疫反应。
影响因子：
7.3
作者：
Chan RWY;Liu S;Cheung JY;Tsun JGS;Chan KC;Chan KYY;Fung GPG;Li AM;Lam HS
通讯作者：
Lam HS
影响因子：
5.4
作者：
Kim, Eun;Okada, Kaori;Gambotto, Andrea
通讯作者：
Gambotto, Andrea
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group